Pregabalin
Product Images NDC 68071-2820

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68071-2820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2820 6)

Pregabalin 100 mg capsules packaging label from NuCare Pharmaceuticals, Inc. The label shows a quantity of 60 capsules. It includes the product number P2249060 and drug form as oblong orange opaque capsules imprinted with "SG" on the cap and "353" on the body. The label contains various regulatory information including NDC 68071-2820-6 and storage temperature instructions.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent improvement in pain from baseline versus percent of patients improved for Pregabalin at different doses (200 mg, 100 mg, 25 mg three times a day) compared to placebo. The y-axis represents percent of patients improved, and the x-axis represents percent improvement in pain from baseline.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent improvement in pain from baseline with the percent of patients improved for Pregabalin 100 mg three times a day versus placebo. The x-axis shows percent improvement in pain from baseline (0 to 100), and the y-axis shows percent of patients improved (0 to 100). Two lines represent Pregabalin treatment and placebo outcomes across the range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved based on percent improvement in pain from baseline. It compares Pregabalin at 75 mg, 150 mg, and 300 mg taken two times a day with a placebo, illustrating the variation in patient improvement across different doses.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating higher improvement percentages with the 200 mg dose, followed by the 100 mg dose, then placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows three curves depicting the improvement rates of each treatment group.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph comparing responder rates (%) across different doses of pregabalin in Studies E1 and E3. The x-axis shows doses and placebo groups, while the y-axis shows responder rates. Higher doses show increased responder rates with statistical significance noted versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day. It includes data points from four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, with significant p-values noted for various doses. Dose values range from 0 to 600 mg/day, and seizure reduction ranges from 0 to 60 percent.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph illustrating the percent of patients improved versus the percent improvement in pain from baseline, comparing Pregabalin doses of 800 mg, 450 mg, 300 mg daily, and placebo. The graph shows four curves representing each treatment group's response over a range of pain improvement percentages from 0 to 100%.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph showing the estimated percentage of subjects without LTR over 180 days comparing Pregabalin and placebo. The y-axis represents the estimated percent of subjects without LTR, and the x-axis represents the number of days. The solid line represents Pregabalin, and the dashed line represents placebo, with Pregabalin consistently showing a higher percentage over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A Kaplan-Meier curve chart showing the percentage of subjects improved over time from baseline to Week 12 for Pregabalin compared to Placebo. The x-axis represents percent improvement from baseline, and the y-axis shows the percent of subjects improved. Two lines depict the therapeutic effect of Pregabalin (solid line) versus Placebo (dashed line).*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved between Pregabalin and placebo groups from baseline to week 16. The X-axis represents the percent improvement from 0 to 100, and the Y-axis represents the percentage of subjects improved, from 0% to 100%. Two lines show the trends, with Pregabalin generally demonstrating a higher percentage of improved subjects across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine, with a multiplication adjustment for female patients. This text panel provides dosing calculation information relevant to drug treatment considerations.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of the active ingredient Pregabalin, showing its molecular layout with labeled functional groups including an amine (NH2) and a carboxylic acid (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.